J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Updates From Pfizer, Merck & Co., AbbVie, Novartis, Sanofi, Biogen
Executive Summary
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.
You may also be interested in...
AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.
Sanofi Bids €308m To Buy Kiadis
Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."
Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds
Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.
Need a specific report? 1000+ reports available
Buy Reports